- Home
- MYGN vs PAXS Comparison
MYGN vs PAXS Comparison
Compare MYGN & PAXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- PAXS
- Stock Information
- Founded
- MYGN 1991
- PAXS 2021
- Country
- MYGN United States
- PAXS United States
- Employees
- MYGN N/A
- PAXS N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- PAXS Investment Managers
- Sector
- MYGN Health Care
- PAXS Finance
- Exchange
- MYGN Nasdaq
- PAXS Nasdaq
- Market Cap
- MYGN 625.5M
- PAXS 708.1M
- IPO Year
- MYGN 1995
- PAXS N/A
- Fundamental
- Price
- MYGN $6.65
- PAXS $15.74
- Analyst Decision
- MYGN Hold
- PAXS
- Analyst Count
- MYGN 14
- PAXS 0
- Target Price
- MYGN $13.23
- PAXS N/A
- AVG Volume (30 Days)
- MYGN 1.1M
- PAXS 195.0K
- Earning Date
- MYGN 11-03-2025
- PAXS 01-01-0001
- Dividend Yield
- MYGN N/A
- PAXS 11.72%
- EPS Growth
- MYGN N/A
- PAXS N/A
- EPS
- MYGN N/A
- PAXS N/A
- Revenue
- MYGN $825,300,000.00
- PAXS N/A
- Revenue This Year
- MYGN $0.06
- PAXS N/A
- Revenue Next Year
- MYGN $5.68
- PAXS N/A
- P/E Ratio
- MYGN N/A
- PAXS N/A
- Revenue Growth
- MYGN 0.21
- PAXS N/A
- 52 Week Low
- MYGN $3.76
- PAXS $12.57
- 52 Week High
- MYGN $16.83
- PAXS $15.93
- Technical
- Relative Strength Index (RSI)
- MYGN 41.25
- PAXS 42.90
- Support Level
- MYGN $6.25
- PAXS $15.72
- Resistance Level
- MYGN $6.83
- PAXS $16.08
- Average True Range (ATR)
- MYGN 0.43
- PAXS 0.19
- MACD
- MYGN -0.09
- PAXS 0.00
- Stochastic Oscillator
- MYGN 23.90
- PAXS 10.75
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About PAXS PIMCO Access Income Fund of Beneficial Interest
PIMCO Access Income Fund is a non-diversified, limited-term, closed-end management investment company. The fund seeks current income as an objective and capital appreciation as a secondary objective. It achieves the investment objectives by utilizing a dynamic asset allocation among multiple sectors in the public and private credit markets, including corporate debt.